Antiplatelet therapy and anticoagulant therapy are the foundations for the treatment of acute coronary syndromes (ACS). Join Dr Eric Bates and panelists Drs Gabriel Steg, Robert Storey and Steen Dalby Kristensen as they discuss new guideline recommendations for the use of antiplatelet therapy and anticoagulant therapy in patients experiencing an acute coronary syndrome (ACS).

An investigator and clinical scholar, Dr. Christopher Granger, MD, the program chairman, and his distinguished colleagues illuminate the emerging threats and clinical challenges cardiologists face when managing patients who present with, or undergo, acute, severe, serious, precipitous, and/or life-threatening elevations in systemic blood pressure.

Distinguished faculty members of The Year 2008 EDICT (Emergency Department and Interventional Cardiology Therapeutic teams) for ACS initiative are pleased to invite you to participate in a regional, science-to-strategy summit focused on upstream and downstream management of patients with STEMI and UA/NSTEMI.

This program will address new dimensions and practice advances with scientific rigor and expert analysis, including case studies.

Important issues surrounding the care of patients with acute coronary syndrome (ACS) - the safety and efficacy of medical management vs invasive strategies and balancing efficacy against the increased risk for bleeding - have been discussed at several recent meetings. The volume of newly released data surrounding the treatment of patients with ACS has led to confusion as to what is the best therapeutic option for a given patient. Join Ph Gabriel Steg MD and panelists Christian Hamm MD and Harvey White MD as they contextualize these data and discuss the applicability to clinical practice

Antiplatelet therapy involves a balance between the prevention of thrombosis and bleeding. The AHA 2007 Scientific Sessions program included the long-awaited results from TRITON and presentations on areas of uncertainty, including cost-effectiveness, loading dose, duration of therapy and resistance.

The volume of recently released - and sometimes conflicting - clinical trial data surrounding the treatment of patients with ACS has led to confusion as to what is the best therapeutic option for a given patient. Because of the varying results from these trials, clinicians currently struggle with what constitutes optimum antithrombin/antiplatelet strategy for patients with ACS. Join Dr Eric Bates and panelists Drs Peter Berger and Gregg Stone as they contextualize these data and discuss their applicability to clinical practice.

Join Drs Ferguson, Bhatt, and Stone as they discuss the new ACC/AHA guidelines for the management of UA/NSTEMI; from the choice of an initial invasive or conservative strategy to the myriad pharmacologic options, what's a cardiologist to do?

Pharmacologic treatment in ACS involves a careful balance of safety and efficacy since bleeding has emerged as a major predictor of adverse outcomes, including mortality. Hear Dr Gregg Stone present the interesting results of the HORIZONS AMI trial, which pitches bivalirudin against heparin+glycoprotein IIb/IIIa in STEMI patents undergoing primary PCI. Then listen to Drs William Knopf and Michael Lincoff give their response to the findings.